Product Development Partnerships (PDPs) have played an important role in
improving the funding and accelerating development of novel and much
needed interventions to address issues of global health, especially for
poor and disadvantaged populations. Through their ability to bring
together partners from academia, industry, the public sector and
multilateral agencies to develop effective, affordable, appropriate and
accessible products, PDPs have also stimulated increased collaboration
of the pharmaceutical industry to work on the diseases of poverty (DoP).
The aim of this report is to provide information to The UK Department
for International Development (DFID) and the German Ministry for
Education and Research (BMBF) about the value of their current
investments and help making informed decisions on future PDP investments
through an evaluation of the operations and performance of Foundation
for Innovative New Diagnostics (FIND) and Drugs for Neglected Diseases
initiative (DNDi) over the period 2009-2013. In addition, the
performance and operation of the European Vaccine Initiative (EVI) over
the period 2009-13 was assessed building on the results of an existing
external review of EVI which was carried out in 2012-2013.
This evaluation included a thorough review and analysis of relevant
documentation and interviews with stakeholders of DNDi and FIND, members
of the PDPs’ boards, steering committees, and advisory boards, the PDP
Funders Group, key informants at WHO, Global Health Partnerships, EDCTP,
and other multilaterals, private sector partners of the PDPs and
The overall recommendations are:
- Public funders should continue to support PDPs with long-term
financing in order to ensure there is a steady stream of needed
interventions for neglected infectious diseases. This funding should
be mostly unrestricted or semi-restricted.
- All PDPs should seek to diversify their funding base (as DNDi is
doing) in order to ensure that they have the flexibility to set and
follow their own strategy and not be driven by the requirements of one
- Funders should agree amongst themselves on the measures of impact and
value for money, and to give clear guidance to PDPs (amongst others)
to ensure comparisons can be made in a consistent manner.
Boulton, I.; Meredith, S.; Mertenskoetter, T.; Glaue, F. Evaluation of the Product Development Partnerships (PDP) funding activities. (2015) 71 pp.
Evaluation of the Product Development Partnerships (PDP) funding activities